2. Academic Validation
  3. Veliparib overcomes multidrug resistance in liver cancer cells

Veliparib overcomes multidrug resistance in liver cancer cells

  • Biochem Biophys Res Commun. 2020 Jan 15;521(3):596-602. doi: 10.1016/j.bbrc.2019.10.141.
Lin Chang 1,  Yulan Hou 2,  Lili Zhu 2,  Zhixue Wang 2,  Guotao Chen 3,  Chengfeng Shu 2,  Yali Liu 2
Affiliations

Affiliations

  • 1 Department of Laboratory Medicine, Bishan Hospital, Chongqing, China. Electronic address: [email protected].
  • 2 Department of Laboratory Medicine, Bishan Hospital, Chongqing, China.
  • 3 Department of Nephrology, Bishan Hospital, Chongqing, China.
PMID: 31679697 DOI: 10.1016/j.bbrc.2019.10.141
Abstract

Overexpression of ATP-binding cassette (ABC) transporter is one of the most important factors taking responsibility for the progress of multidrug resistance (MDR) in multiple cancers. In this study, we investigated that veliparib, a PARP Inhibitor which is in clinical development, could overcome ABCB1-mediated MDR in liver Cancer cells. Veliparib could significantly enhance the cytotoxic effects of a series of conventional chemotherapeutic drugs in ABCB1-overexpression liver Cancer cells. Mechanism study showed that veliparib could significantly enhance the accumulation of doxorubicin in ABCB1-overexpression liver Cancer cells, without down-regulating the expression level of ABCB1. Finally, veliparib could significantly inhibit the ATPase activity of ABCB1 transporter. This study could provide information that combine veliparib with other chemotherapeutic drugs may benefit liver Cancer patients.

Keywords

ABC transporter; Liver cancer; Multidrug resistance (MDR); Veliparib.

Figures
Products